Kidney Failure, Chronic
Conditions
Keywords
ketone, acetoacetate, acetate
Brief summary
The objective of this study is to nake a comparison between 11c-acetate and 11c-acetoacetate kidney uptake in chronic kidney failure patients.
Detailed description
Chronic kidney failure patients will be ask to perform two positron emission tomography scan during the same day. One, with a 11C-Acetate Tracer and the other with 11C-Acetoacetate. The results will allow to determine the difference between the two tracers and will ultimately be compared with precedent results of healthy controls.
Interventions
RADIATIONPET scan metabolic day
11C-Acetate and 11C-Acetoacetate PET scans
Sponsors
Nestle Health Science
Université de Sherbrooke
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* BMI between 18.5 and 40 * Kidney failure if GFR betweem 30 and 60 mL/min/1.73m2 * Stable medication for at least 4 weeks
Exclusion criteria
1. Receive cytotoxic therapy for primary or secondary kidney disease within 6 months prior to enrollment 2. Organ Transplant History 3. Class IV congestive heart failure (New York Heart Association) 4. Myocardial infarction, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrollment 5. Coronary revascularization (percutaneous coronary intervention or arterial bypass) or valve repair/replacement within 12 weeks of enrollment or is scheduled to undergo one of these procedures within 4 weeks of enrollment 6. Any condition outside the realm of renal and cardiovascular disease, such as, but not limited to, malignancy, with a life expectancy of less than 2 years in the clinical judgment of the investigator 7. Active malignancy requiring treatment at Visit 1 (except successfully treated basal or squamous cell carcinoma). 8. Hepatic impairment (aspartate transaminase or alanine transaminase \>3x upper limit of normal; or total bilirubin \>2x upper limit of normal at time of enrollment 9. Pregnancy or lactation 10. Adherence to a ketogenic diet, consumption of ketogenic products or supplements or intermittent fasting or other diet or supplements that may significantly increase ketones in the past two months. 11. Daily alcohol consumption \>2 servings per day 12. Participation in other interventional research projects concurrently or participation in other PET research projects in the last year, which exceeds the recommended limits 13. Inability to lie still in supine position; 14. Medical fluid restriction limiting fluid intake for the procedure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean in kidney acetate uptake | 30 minutes | Kidney acetate uptake measured by pet scan |
| Mean in kidney acetoacetate uptake | 30 minutes | Kidney acetoacetate uptake measured by pet scan |
| Mean in kidney acetoacetate metabolism | 30 minutes | Kidney acetoacetate metabolism measured by pet scan |
| Mean in kidney acetate metabolism | 30 minutes | Kidney acetate metabolism measured by pet scan |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean in heart ejection fraction | 30 minutes | Ejection fraction measured by pet scan |
Countries
Canada
Contacts
Primary ContactValerie St-Pierre, MSc
Outcome results
None listed